Providing a comprehensive postmortem genetic evaluation in the setting of a sudden death attributed to thoracic aortic dissection or with a personal or family history suggestive of Marfan syndrome, Loeys-Dietz syndrome, thoracic aortic aneurysm and dissections, or a related disorder
Identification of a pathogenic variant in the decedent, which may assist with risk assessment and predictive testing of at-risk family members
This test includes next-generation sequencing and supplemental Sanger sequencing to evaluate for variants in the ACTA2, CBS, COL3A1, FBN1, FBN2, MYH11, MYLK, SKI, SLC2A10, SMAD3, TGFB2, TGFBR1, and TGFBR2 genes.
This test is intended for use on postmortem samples (eg, formalin-fixed, paraffin-embedded [FFPE] tissue block) when whole blood is not available.
This test uses next-generation sequencing to test for variants in the ACTA2, CBS, COL3A1, FBN1, FBN2, MYH11, MYLK, SKI, SLC2A10, SMAD3, TGFB2, TGFBR1, and TGFBR2 genes.
This test may aid in the postmortem diagnosis of Marfan syndrome, Loeys-Dietz syndrome, familial thoracic aortic aneurysm and dissection (TAAD), or a related disorder.
Identification of a pathogenic variant may assist with familial risk assessment, screening, and genetic counseling.
